Exosomes secreted by apoptosis-resistant Acute Myeloid Leukemia (AML) blasts harbor regulatory network proteins potentially involved in antagonism of apoptosis

Molecular and Cellular Proteomics

Volumn 15, Issue 4, 2016, Pages 1281-1298

  Wojtuszkiewicz, Anna ^a   Schuurhuis, Gerrit J ^a   Kessler, Floortje L ^a   Piersma, Sander R ^a   Knol, Jaco C ^a   Pham, Thang V ^a   Jansen, Gerrit ^b   Musters, René J P ^c   Van Meerlo, Johan ^a   Assaraf, Yehuda G ^d   Kaspers, Gertjan J L ^a   Zweegman, Sonja ^a   Cloos, Jacqueline ^a   Jimenez, Connie R ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b University of Amsterdam   (Netherlands)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; BETA TUBULIN; BOLA LIKE PROTEIN 2; CALPONIN 2; CHAPERONIN 60; CHROMOBOX PROTEIN HOMOLOG 5; COILIN PROTEIN; DEOXYCYTIDINE KINASE; FATTY ACID SYNTHASE; HEME OXYGENASE 2; HISTONE DEACETYLASE 2; INTERLEUKIN 16; LYMPHOCYTE SPECIFIC PROTEIN 1; MESSENGER RNA; MINICHROMOSOME MAINTENANCE PROTEIN 6; NUCLEASE SENSITIVE ELEMENT BINDING PROTEIN 1; PREFOLDIN SUBUNIT 2; PROTEASOME ASSEMBLY CHAPERONE 3; PROTEASOME ASSEMBLY CHAPERONE 4 PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; RAB5B PROTEIN; RETINOBLASTOMA BINDING PROTEIN 7; RHO ASSOCIATED PROTEIN KINASE 1; SIGNAL RECOGNITION PARTICLE 14 KDA PROTEIN; SPLICING FACTOR 3B SUBUNIT 1; SPLICING FACTOR ARGININE SERINE RICH 9 PROTEIN; UBIQUITIN CONJUGATING ENZYME E2L 6 ISOFORM 1; UNCLASSIFIED DRUG; PROTEOME;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER CHEMOTHERAPY; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; EX VIVO STUDY; EXOSOME; FEMALE; GENE CONTROL; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHOCYTE; MAJOR CLINICAL STUDY; MICROENVIRONMENT; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; RNA SPLICING; UPREGULATION; ACUTE MYELOID LEUKEMIA; CYTOLOGY; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; METABOLISM; PATHOLOGY; SECRETION (PROCESS); TUMOR CELL CULTURE;

APOPTOSIS; BONE MARROW CELLS; DRUG RESISTANCE, NEOPLASM; EXOSOMES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; LEUKEMIA, MYELOID, ACUTE; PROTEOME; TUMOR CELLS, CULTURED;

EID: 84994840424     PISSN: 15359476     EISSN: 15359484     Source Type: Journal    
DOI: 10.1074/mcp.M115.052944     Document Type: Article

References (54)

1. Cornelissen, J. J., van Putten, W. L., Verdonck, L. F., Theobald, M., Jacky, E., Daenen, S. M., van Marwijk Kooy, M., Wijermans, P., Schouten, H., Huijgens, P. C., van der Lelie, H., Fey, M., Ferrant, A., Maertens, J., Gratwohl, A., and Lowenberg, B. (2007) Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: Benefits for whom? Blood 109, 3658-3666
2. Kaspers, G. J. L. (2012) Pediatric acute myeloid leukemia. Expert Rev. Anticancer Ther. 12, 405-413
3. Campos, L., Rouault, J. P., Sabido, O., Oriol, P., Roubi, N., Vasselon, C., Archimbaud, E., Magaud, J. P., and Guyotat, D. (1993) High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81, 3091-3096
4. Del Poeta, G., Venditti, A., Del Principe, M. I., Maurillo, L., Buccisano, F., Tamburini, A., Cox, M. C., Franchi, A., Bruno, A., Mazzone, C., Panetta, P., Suppo, G., Masi, M., and Amadori, S. (2003) Amount of spontaneous apoptosis detected by BAX/BCL-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 101, 2125-2131
5. Sharawat, S. K., Bakhshi, R., Vishnubhatla, S., Gupta, R., and Bakhshi, S. (2013) BAX/BCL2 RMFI ratio predicts better induction response in pediatric patients with acute myeloid leukemia. Pediatr. Blood Cancer 60, E63-E66
6. van Stijn, A., Kok, A., van der Pol, M. A., Feller, N., Roemen, G. M., Westra, A. H., Ossenkoppele, G. J., and Schuurhuis, G. J. (2003) A flow cytometric method to detect apoptosis-related protein expression in minimal residual disease in acute myeloid leukemia. Leukemia 17, 780-786
7. van Stijn, A., Feller, N. Kok, A., van der Pol, M. A., Ossenkoppele, G. J., and Schuurhuis, G. J. (2005) Minimal residual disease in acute myeloid leukemia is predicted by an apoptosis-resistant protein profile at diagnosis. Clin. Cancer Res. 11, 2540-2546
8. Terwijn, M., van Putten, W. L., Kelder, A., van der Velden, V. H. J., Brooimans, R. A., Pabst, T., Maertens, J., Boeckx, N., de Greef, G. E., Valk, P. J., Preijers, F. W., Huijgens, P. C., Dräger, A. M., Schanz, U., Jongen-Lavrecic, M., Biemond, B. J., Passweg, J. R., van Gelder, M., Wijermans, P., Graux, C., Bargetzi, M., Legdeur, M.-C., Kuball, J., de Weerdt, O., Chalandon, Y., Hess, U., Verdonck, L. F., Gratama, J. W., Oussoren, Y. J., Scholten, W. J., Slomp, J., Snel, A. N., Vekemans, M.-C., Löwenberg, B., Ossenkoppele, G. J., and Schuurhuis, G. J. (2013) High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: Data from the HOVON/SAKK AML 42A study. J. Clin. Oncol. 31, 3889-3897
9. Venditti, A., Buccisano, F., Del Poeta, G., Maurillo, L., Tamburini, A., Cox, C., Battaglia, A., Catalano, G., Del Moro, B., Cudillo, L., Postorino, M., Masi, M., and Amadori, S. (2000) Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 96, 3948-3952
10. Feller, N., van der Pol, M. A., van Stijn, A., Weijers, G. W., Westra, A. H., Evertse, B. W., Ossenkoppele, G. J., and Schuurhuis, G. J. (2004) MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 18, 1380-1390
11. van Stijn, A., Kok, A., van Stalborch, M. A., van der Pol, M. A., Feller, N., Westra, A. H., Ossenkoppele, G. J., and Schuurhuis, G. J. (2004) Minimal residual disease cells in AML patients have an apoptosis-sensitive protein profile. Leukemia 18, 875- 877
12. Baj-Krzyworzeka, M., Szatanek, R., Weglarczyk, K., Baran, J., and Zembala, M. (2007) Tumour-derived microvesicles modulate biological activity of human monocytes. Immunol. Lett. 113, 76-82
13. Roccaro, A., Sacco, A., Maiso, P., Azab, A. K., Tai, Y.-T., Reagan, M., Azab, F., Flores, L. M., Campigotto, F., Weller, E., Anderson, K. C., Scadden, D. T., and Ghobrial, I. M. (2013) BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J. Clin. Invest. 123, 1542-1555
14. Buggins, A. G., Milojkovic, D., Arno, M. J., Lea, N. C., Mufti, G. J., Thomas, N. S., and Hirst, W. J. (2001) Microenvironment produced by acute myeloid leukemia cells prevents T cell activation and proliferation by inhibition of NF-kappaB, c-Myc, and pRb pathways. J. Immunol. 167, 6021- 6030
15. Lotem, J., and Sachs, L. (1999) Cytokines as suppressors of apoptosis. Apoptosis 4, 187-196
16. Ryningen, A., Wergeland, L., Glenjen, N., Gjertsen, B. T., and Bruserud, O. (2005) In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proangiogenic Interleukin 8. Leuk. Res. 29, 185-196
17. Macanas-Pirard, P., Leisewitz, A., Broekhuizen, R., Cautivo, K., Barriga, F. M., Leisewitz, F., Gidi, V., Riquelme, E., Montecinos, V. P., Swett, P., Besa, P., Ramirez, P., Ocqueteau, M., Kalergis, A. M., Holt, M., Rettig, M., DiPersio, J. F., and Nervi, B. (2012) Bone marrow stromal cells modulate mouse ENT1 activity and protect leukemia cells from cytarabine induced apoptosis. PLoS ONE 7, e37203
18. Ratajczak, J., Wysoczynski, M., Hayek, F., Janowska-Wieczorek, A., and Ratajczak, M. Z. (2006) Membrane-derived microvesicles: Important and underappreciated mediators of cell-to-cell communication. Leukemia 20, 1487-1495
19. Milojkovic, D., Devereux, S., Westwood, N. B., Mufti, G. J., Thomas, N. S., and Buggins, A. G. S. (2004) Antiapoptotic microenvironment of acute myeloid leukemia. J. Immunol. 173, 6745-6752
20. Lacombe, F., Durrieu, F., Briais, A., Dumain, P., Belloc, F., Bascans, E., Reiffers, J., Boisseau, M. R., and Bernard, P. (1997) Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia 11, 1878-1886
21. van Stijn, A., Kok, A., van der Pol, M. A., Feller, N., Roemen, G. M., Westra, A. H., Ossenkoppele, G. J., and Schuurhuis, G. J. (2003) Multiparameter flow cytometric quantification of apoptosis-related protein expression. Leukemia 17, 787-788
22. Piersma, S. R., Fiedler, U., Span, S., Lingnau, A., Pham, T. V., Hoffmann, S., Kubbutat, M. H. G., and Jiménez, C. R. (2010) Workflow comparison for label-free, quantitative secretome proteomics for cancer biomarker discovery: method evaluation, differential analysis, and verification in serum. J. Proteome Res. 9, 1913-1922
23. Piersma, S. R., Broxterman, H. J., Kapci, M., de Haas, R. R., Hoekman, K., Verheul, H. M. W., and Jiménez, C. R. (2009) Proteomics of the TRAPinduced platelet releasate. J. Proteomics 72, 91-109
24. Warmoes, M., Jaspers, J. E., Pham, T. V., Piersma, S. R., Oudgenoeg, G., Massink, M. P. G., Waisfisz, Q., Rottenberg, S., Boven, E., Jonkers, J., and Jimenez, C. R. (2012) Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer. Mol. Cell. Proteomics 11, M111.013334
25. Piersma, S. R., Warmoes, M. O., de Wit, M., de Reus, I., Knol, J. C., and Jiménez, C. R. (2013) Whole gel processing procedure for GeLC-MS/MS based proteomics. Proteome Science 11, 17
26. Warmoes, M., Jaspers, J. E., Xu, G., Sampadi, B. K., Pham, T. V., Knol, J. C., Piersma, S. R., Boven, E., Jonkers, J., Rottenberg, S., and Jimenez, C. R. (2013) Proteomics of genetically engineered mouse mammary tumors identifies fatty acid metabolism members as potential predictive markers for cisplatin resistance. Mol. Cell. Proteomics 12, 1319-1334
27. Nesvizhskii, A. I., Keller, A., Kolker, E., and Aebersold, R. (2003) A statistical model for identifying proteins by tandem mass spectrometry. Anal. Chem. 75, 4646-4658
28. Keller, A., Nesvizhskii, A. I., Kolker, E., and Aebersold, R. (2002) Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal. Chem. 74, 5383-5392
29. Cox, J., and Mann, M. (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367-1372
30. Vizcaíno, J., Deutsch, E., Wang, R., Csordas, A., Reisinger, F., Ríos, D., Dianes, J., Sun, Z., Farrah, T., Bandeira, N., Binz, P., Xenarios, I., Eisenacher, M., Mayer, G., Gatto, L., Campos, A., Chalkley, R., Kraus, H., Albar, J., Martinez-Bartolomé, S., Apweiler, R., Omenn, G., Martens, L., Jones, A., and Hermjakob, H. (2014) ProteomeXchange provides globally co-ordinated proteomics data submission and dissemination. Nat. Biotechnol. 32, 223-226
31. Pham, T. V., Piersma, S. R., Warmoes, M., and Jimenez, C. R. (2010) On the beta-binomial model for analysis of spectral count data in label-free tandem mass spectrometry-based proteomics. Bioinformatics 26, 363-369
32. Szklarczyk, D., Franceschini, A., Kuhn, M., Simonovic, M., Roth, A., Minguez, P., Doerks, T., Stark, M., Muller, J., Bork, P., Jensen, L. J., and von Mering, C. (2011) The STRING database in 2011: Functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res. 39, D561-568
33. Smoot, M. E., Ono, K., Ruscheinski, J., Wang, P. L., and Ideker, T. (2011) Cytoscape 2.8: New features for data integration and network visualization. Bioinformatics 27, 431-432
34. Maere, S., Heymans, K., and Kuiper, M. (2005) BiNGO: A Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics 21, 3448-3449
35. Nepusz, T., Yu, H., and Paccanaro, A. (2012) Detecting overlapping protein complexes in protein-protein interaction networks. Nat. Methods 9, 471-472
36. Théry, C., and Amigorena, S. (2006) Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr. Protoc. Cell Biol. 30, 3.22.1-29.
37. Chiasserini, D., van Weering, J. R., Piersma, S. R., Pham, T. V., Malekzadeh, A., Teunissen, C. E., de Wit, H., and Jiménez, C. R. (2014) Proteomic analysis of cerebrospinal fluid extracellular vesicles: A comprehensive dataset. J. Proteomics 106, 191-204
38. Becker, H., Marcucci, G., Maharry, K., Radmacher, M. D., Mrózek, K., Margeson, D., Whitman, S. P., Wu, Y.-Z., Schwind, S., Paschka, P., Powell, B. L., Carter, T. H., Kolitz, J. E., Wetzler, M., Carroll, A. J., Baer, M. R., Caligiuri, M. A., Larson, R. A., and Bloomfield, C. D. (2010) Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: A Cancer and Leukemia Group B study. J. Clin. Oncol. 28, 596-604
39. van Stijn, A., van der Pol, M., Kok, A., Bontje, P. M., Roemen, G. M. J. M., Beelen, R. H. J., Ossenkoppele, and G. J., Schuurhuis, G. J. (2003) Differences between the CD34ô and CD34-blast compartments in apoptosis resistance in acute myeloid leukemia. Haematologica 88, 497-508
40. Schwerk, C., and Schulze-Osthoff, K. (2005) Regulation of apoptosis by alternative pre-mRNA splicing. Mol. Cell 19, 1-13
41. Akgul, C., Moulding, D. A., and Edwards, S. W. (2004) Alternative splicing of Bcl-2-related genes: Functional consequences and potential therapeutic applications. Cell. Mol. Life Sci. 61, 2189-2199
42. Moore, M. J., Wang, Q., Kennedy, C. J., and Silver, P. A. (2010) An alternative splicing network links cell-cycle control to apoptosis. Cell 142, 625-636
43. Cloutier, P., Toutant, J., Shkreta, L., Goekjian, S., Revil, T., and Chabot, B. (2008) Antagonistic effects of the SRp30c protein and cryptic 5' splice sites on the alternative splicing of the apoptotic regulator BCL-x. J. Biol. Chem. 283, 21315-21324
44. Jiang, Z. H., Zhang, W. J., Rao, Y., and Wu, J. Y. (1998) Regulation of Ich-1 pre-mRNA alternative splicing and apoptosis by mammalian splicing factors. Proc. Natl. Acad. Sci. U.S.A. 95,
45. Verhaak, R. G., Goudswaard, C. S., van Putten, W., Bijl, M. A., Sanders, M. A., Hugens, W., Uitterlinden, A. G., Erpelinck, C. A., Delwel, R., Löwenberg, B., and Valk, P. J. (2005) Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): Association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 106, 3747-3754
46. Hsu, C. Y., and Yung, B. Y. (2000) Over-expression of nucleophosmin/B23 decreases the susceptibility of human leukemia HL-60 cells to retinoic acid-induced differentiation and apoptosis. Int. J. Cancer 88, 392- 400
47. Colombo, E., Bonetti, P., Denchi, E. L., Martinelli, P., Zamponi, R., Marine, J. C., Helin, K., Falini, B., and Pelicci, P. G. (2005) Nucleophosmin is required for DNA integrity and p19Arf protein stability. Mol. Cell. Biol. 25, 8874-8886
48. Schaaij-Visser, T. B. M., de Wit, M., Lam, S. W., and Jiménez, C. R. (2013) The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context. Biochim. Biophys. Acta 1834, 2242-2258
49. De Wit, M., Kant, H., Piersma, S. R., Pham, T. V., Mongera, S., van Berkel, M. P., Boven, E., Pontén, F., Meijer, G. A., Jimenez, C. R., and Fijneman, R. J. (2014) Colorectal cancer candidate biomarkers identified by tissue secretome proteome profiling. J. Proteomics 99, 26-39
50. Tauro, B. J., Mathias, R. A., Greening, D. W., Gopal, S. K., Ji, H., Kapp, E. A., Coleman, B. M., Hill, A. F., Kusebauch, U., Hallows, J. L., Shteynberg, D., Moritz, R. L., Zhu, H.-J., and Simpson, R. J. (2013) Oncogenic H-ras reprograms Madin-Darby canine kidney (MDCK) cell-derived exosomal proteins following epithelial-mesenchymal transition. Mol. Cell. Proteomics 12, 2148-2159
51. Shibayama, H., Takai, E., Matsumura, I., Kouno, M., Morii, E., Kitamura, Y., Takeda, J., and Kanakura, Y. (2004) Identification of a cytokine-induced antiapoptotic molecule anamorsin essential for definitive hematopoiesis. J. Exp. Med. 199, 581-592
52. Yu, Y., Xie, M., Kang, R., Livesey, K. M., Cao, L., and Tang, D. (2012) HMGB1 is a therapeutic target for leukemia. Am. J. Blood Res. 2, 36-43
53. EL Andaloussi, S., Mäger, I., Breakefield, X. O., and Wood, M. J. (2013) Extracellular vesicles: Biology and emerging therapeutic opportunities. Nat. Rev. Drug Discov. 12, 347-357
54. Huan, J., Hornick, N. I., Shurtleff, M. J., Skinner, A. M., Goloviznina, N. A., Roberts, C. T., and Kurre, P., Jr. (2013) RNA trafficking by acute myelogenous leukemia exosomes. Cancer Res. 73, 918-929